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Clinical Infectious Diseases
M A J O R A R T I C L E
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Culture to Identify Pulmonary Tuberculosis in Patients
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(See the Editorial Commentaries by DiNardo, Lange, and Mandalakas on pages 1089–91.)
Background. The Xpert MTB/RIF (Xpert) assay is a rapid nucleic acid amplification test widely used in settings of high tuber-
culosis prevalence to detect tuberculosis as well as rpoB mutations associated with rifampin resistance. Data are needed on the di-
agnostic performance of Xpert in lower-prevalence settings to inform appropriate use for both tuberculosis detection and the need
for respiratory isolation.
Methods. Xpert was compared to 2 sputum samples, each evaluated with acid-fast bacilli (AFB) smear and mycobacterial culture
using liquid and solid culture media, from participants with suspected pulmonary tuberculosis from the United States, Brazil, and
South Africa.
Results. Of 992 participants enrolled with evaluable results, 22% had culture-confirmed tuberculosis. In 638 (64%) US partic-
ipants, 1 Xpert result demonstrated sensitivity of 85.2% (96.7% in participants with AFB smear-positive [AFB+] sputum, 59.3% with
AFB smear-negative [AFB–] sputum), specificity of 99.2%, negative predictive value (NPV) of 97.6%, and positive predictive value of
94.9%. Results did not differ between higher- and low-prevalence settings. A second Xpert assay increased overall sensitivity to 91.1%
(100% if AFB+, 71.4% if AFB–), with specificity of 98.9%. In US participants, a single negative Xpert result predicted the absence of
AFB+/culture-positive tuberculosis with an NPV of 99.7%; NPV of 2 Xpert assays was 100%, suggesting a role in removing patients
from airborne infection isolation. Xpert detected tuberculosis DNA and mutations associated with rifampin resistance in 5 of 7 par-
ticipants with rifampin-resistant, culture-positive tuberculosis. Specificity for rifampin resistance was 99.5% and NPV was 98.9%.
Conclusions. In the United States, Xpert testing performed comparably to 2 higher-tuberculosis-prevalence settings. These data
support the use of Xpert in the initial evaluation of tuberculosis suspects and in algorithms assessing need for respiratory isolation.
Keywords. Xpert MTB/RIF; tuberculosis diagnosis; respiratory isolation; nontuberculous mycobacteria; HIV/tuberculosis
coinfection.
The Xpert MTB/RIF (Xpert) assay (Cepheid, Sunnyvale, Cali-
fornia) is an automated nucleic acid amplification test that
can detect both Mycobacterium tuberculosis and mutations
associated with rifampin resistance in <2 hours with minimal
hands-on time and technical expertise. In previous studies,
Xpert demonstrated a pooled specificity of 99% and sensitivity
of 98% in acid-fast bacilli smear-positive (AFB+) and 67% in
AFB smear-negative (AFB–) sputum specimens in mostly high-
tuberculosis-prevalence settings [1].Xpert testing has been widely
implemented in resource-limited settings with high tuberculosis
prevalence and as a frontline tuberculosis diagnostic in patients
infected with human immunodeficiency virus (HIV) [2].
Xpert was authorized by the US Food and Drug Admini-
stration (FDA) in 2013 for detection of M. tuberculosis and
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reporting of rifampin resistance directly from sputum samples
[3] and as an aid in decisions regarding respiratory isolation in
2015 [4]. However, published data for Xpert use in settings of
low tuberculosis prevalence such as the United States are limit-
ed. Lower tuberculosis prevalence may impact positive and neg-
ative predictive values, and data for Xpert performance in
clinical settings where nontuberculous mycobacteria (NTM)
are common are also limited.
We conducted a longitudinal multicenter study to evaluate
Xpert performance in the United States in comparison to 2
higher-tuberculosis-prevalence settings: Rio de Janeiro, Brazil
(local annual tuberculosis incidence of 96.9/100 000 [5]), and
Johannesburg, South Africa (annual tuberculosis incidence of
466/100 000 [6]).
METHODS
Participants
Individuals aged ≥18 years undergoing evaluation for pulmo-
nary tuberculosis (defined as individuals with cough, fever,
night sweats, or weight loss who had sputum tested by AFB
smear and culture) were enrolled from 21 sites in the United
States and a site from Rio de Janeiro, Brazil, and Johannesburg,
South Africa. Participants received <48 hours of tuberculosis
treatment in the 6 months prior to sputum collection for
Xpert testing. All were tested for HIV infection.
Specimen Collection and Processing
All participants provided 2 sputum specimens for AFB smear
with fluorescent staining and mycobacterial culture (using both
liquid and solid media), conducted according to the local standard
of care. Results from additional AFB smears and cultures were
recorded. Mycobacterial species identification was by FDA-
approved methods, and participants with M. tuberculosis growth
had 1 culture tested for rifampin susceptibility using proportions
method on Middlebrook agar [7] as well as rpoB gene sequencing
[8]. Xpert testing was conducted on either residual sputum after
processing for AFB smear/cultures or on additional sputum spec-
imens collected within 7 days of the 2 required AFB smears and
cultures. Xpert testing was conducted according to the manufac-
turer’s recommendations [9] within 7 days of specimen collection
at 2 US laboratories and locally at laboratories in Brazil and South
Africa. If initial Xpert results were invalid, testing was repeated
using the same specimen when the sample volume was adequate.
Sputum processing (concentrated vs unconcentrated) andmethod
of collection (induced vs expectorated) were determined by speci-
men availability and the local standard of care. See Supplementary
Appendix for additional details.
Statistical Methods
The primary objectives of this study were to estimate sensitivity
of 1 Xpert assay in AFB+ participants and in AFB– participants
and specificity among US participants compared with the re-
sults of mycobacterial culture. Sample size for this study was
determined within each subgroup, based on the point estimates
and 95% confidence intervals (CIs) reported in a prior study
[10]. This study was not powered for the comparisons made
in the secondary objectives; no adjustments were made for mul-
tiple comparisons. Unless otherwise specified, all secondary
analyses were planned. AFB+ status was defined as at least 1
of the 2 sputum specimens having ≥1 positive AFB smear. Cul-
ture-confirmed tuberculosis was defined as at least 1 of the 4
cultures (2 sputum specimens, each cultured on liquid and
solid media) with M. tuberculosis growth. The reference com-
parator for tuberculosis detection by Xpert assay was culture-
confirmed M. tuberculosis and, for rifampin resistance,
culture-based drug susceptibility testing. The 95% CIs were cal-
culated using the Wilson score binomial method. Comparisons
of sensitivities and specificities between independent and over-
lapped subgroups of interest were assessed using Fisher and
McNemar exact tests, respectively; other statistical comparisons
were done using 2-sided Wilcoxon, Fisher exact, and χ2 tests.
All analyses were done using SAS software version 9.2, with re-
sults considered significant at a level of P < .05.
Human Subjects Review
The protocol was approved by institutional review board/ethics
committee at each site and the Centers for Disease Control and
Prevention.
RESULTS
Study Population
Between May 2012 and November 2013, 1018 participants un-
dergoing evaluation for pulmonary tuberculosis were enrolled,
and 992 were evaluable (Figure 1) . Sixty-four percent (n = 638)
were enrolled from US sites, 20% (n = 199) were from South
Africa, and 16% (n = 155) were from Brazil (Table 1). Thirteen
percent had a history of prior tuberculosis and 19% had initiated
tuberculosis treatment (<48 hours at time of sputum collection).
Seventy-eight percent of US and 21% of non-US participants
were inpatients at the time of evaluation.
AFB Smear Status and Microbiologic Diagnoses
Twenty-two percent of participants had M. tuberculosis re-
covered from 1 or more sputum cultures; 61% had ≥1 AFB+
sputum results. Culture-confirmed tuberculosis was diagnosed
in 14% (92/638) of US participants (68% with AFB+ sputum)
and in 36% (127/354) of participants from non-US sites (55%
with AFB+ sputum). Six percent (57/992) of participants’ cul-
tures failed to growM. tuberculosis but were judged to have clin-
ical tuberculosis on basis of response to empiric treatment.
Twelve percent of US participants had cultures that grew
NTM. Fifteen percent (152/992) of participants had 1 or
more sputum specimens that were AFB+, 88% (133/152) of
whom had M. tuberculosis recovered by culture.
Xpert Assay Performance
Sensitivity of the first Xpert result was 81.4% (Table 2). Sensi-
tivity was 98.5% in AFB+ and 54.8% in AFB– participants. The
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first Xpert result had specificity of 98.7% in participants without
culture-confirmed tuberculosis. In participants from whom
NTM were cultured, the specificity of the first Xpert remained
high at 92% (87/95) and correctly excluded tuberculosis in 93%
(13/14) of AFB+ participants without culture-confirmed tuber-
culosis. The incremental yield of a second Xpert was 35%, iden-
tifying 2 additional participants with AFB+ sputum and 12 with
AFB– sputum, increasing overall per-participant sensitivity to
88.1% (100% in AFB+ and 69.4% in AFB– participants).
The first Xpert was false positive in a total of 10 participants:
1 with AFB+ sputum (Mycobacterium avium complex [MAC]
growth in 2 mycobacteria growth indicator tubes [MGIT] and
2 solid cultures) and 9 participants with AFB– sputum (Supple-
mentary Appendix Table 1). Of the 9 participants with AFB–
sputum, 5 had no mycobacterial growth and 4 had NTM growth
(1 M. abscessus-chelonae, 1 MAC, and 2 NTM not identified to
species level), 2 of whom had M. tuberculosis detected with a
line probe assay (but not by FDA-approved Accuprobe). Testing
with 2 Xpert assays yielded a total of 16 false-positive results, 10
with tuberculosis detected on the first Xpert assay as well. Of the
16 participants with 1 or more positive Xpert results withoutM.
tuberculosis growth, 3 had prior tuberculosis treatment
(completed >6 months prior to Xpert testing). The first Xpert
was falsely negative in 2 participants with AFB+/culture-positive
tuberculosis and 38 participants with AFB–/culture-positive
tuberculosis; 2 of these participants had mixed growth with
M. tuberculosis and NTM.
Low- Versus Higher-Prevalence Settings
In the 618 US participants with both Xpert and mycobacterial
culture results available, 1 Xpert assay demonstrated a sensitivity
of 96.7% in AFB+ participants and 59.3% in AFB– participants,
with a specificity of 99.2%. A second Xpert assay increased overall
sensitivity from 85.2% to 91.1%. In the 342 participants from
Brazil and South Africa, sensitivity was 100% (P = .21) in AFB+
participants and 52.6% (P = .64) in AFB– participants, and spe-
cificity was 97.2% (P = .038) (Table 2).
Xpert Performance in US Respiratory Isolation Algorithm
In comparison to AFB smear as part of the respiratory isolation
algorithm, 2 Xpert assays identified all 62 AFB+/culture-positive
tuberculosis cases, whereas the first Xpert assay identified 96.7%
(59/61) of AFB+/culture-positive tuberculosis cases (Table 3). In
2 instances of AFB+/culture-positive tuberculosis missed by initial
Xpert, testing was performed on an unconcentrated sputum
Figure 1. Flow diagram of diagnostic evaluation of the Xpert MTB/RIF assay in comparison to mycobacterial culture (reported according to Standards for the Reporting of
Diagnostic Accuracy [11]). aMycobacterial culture results were not available for 10 subjects due to contamination (n = 3) or site error (n = 7). Abbreviation: MTB, Mycobacterium
tuberculosis.
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Table 1. Demographics and Baseline Results
Characteristic
Overall
(N = 992)
≥1 Culture TB
Positive (n = 219)
Results of First Xpert Assay (n = 970)a Results of 2 Xpert Assays (n = 990)b
Positive
(n = 187)
Negative
(n = 783)
P
Valuec
Positive
(n = 210)
Negative
(n = 780)
P
Valuec
Age at entry, median (IQR) 46 (35–54) 40 (30–51) 38 (28–51) 47 (37–54) <.001 39 (28–51) 47 (38–55) <.001
Male sex 617 (62.2) 129 (58.9) 116 (19.1) 490 (80.9) .889 130 (21.1) 485 (78.9) .942
Site of enrollment <.001 <.001
Brazil 155 (15.6) 37 (16.9) 32 (20.6) 123 (79.4) 37 (23.9) 118 (76.1)
South Africa 199 (20.1) 90 (41.1) 76 (39.2) 118 (60.8) 84 (42.2) 115 (57.8)
United States 638 (64.3) 92 (42.0) 79 (12.7) 542 (87.3) 89 (14.0) 547 (86.0)
HIV infection status
HIV infected 446 (45.0) 89 (40.6) 71 (16.2) 367 (83.8) .028 85 (19.1) 361 (80.9) .133
On ART at enrollment (HIV infected only)
Yes 155 (34.8) 12 (13.5) 12 (8.1) 137 (91.9) <.001 15 (9.7) 140 (90.3) <.001
No 291 (65.2) 77 (86.5) 59 (20.4) 230 (79.6) 70 (24.1) 221 (75.9)
Presenting symptomsd
Cough 923 (93.0) 205 (93.6) 177 (19.6) 725 (80.4) .322 199 (21.6) 722 (78.4) .267
Fevere 526 (53.0) 122 (55.7) 108 (21.0) 406 (79.0) .118 119 (22.7) 406 (77.3) .052
Weight lossf 608 (61.3) 171 (78.1) 150 (25.2) 446 (74.8) <.001 165 (27.2) 442 (72.8) <.001
Night sweatsg 545 (54.9) 125 (57.1) 106 (20.1) 422 (79.9) .644 123 (22.6) 421 (77.4) .354
Any of the above 982 (99.0) 217 (99.1) 186 (19.4) 774 (80.6) .455 208 (21.2) 772 (78.8) .925
CXR result <.001 <.001
Abnormal 776 (78.2) 197 (90.0) 172 (22.6) 588 (77.4) 190 (24.5) 585 (75.5)
CXR findingsh (abnormal only)
Infiltrate 380 (49.0) 139 (70.6) 124 (33.3) 248 (66.7) <.001 134 (35.4) 245 (64.6) <.001
Cavitation 125 (16.1) 73 (37.1) 74 (59.7) 50 (40.3) <.001 77 (62.1) 47 (37.9) <.001
Pleural effusion 115 (14.8) 25 (12.7) 20 (18.2) 90 (81.8) .228 21 (18.3) 94 (81.7) .091
Other 419 (54.0) 79 (40.1) 70 (16.9) 343 (83.1) <.001 76 (18.2) 342 (81.8) <.001
Location of evaluation
Inpatient 572 (57.7) 98 (44.7) 84 (15.1) 471 (84.9) <.001 92 (16.1) 478 (83.9) <.001
Outpatient 420 (42.3) 121 (55.3) 103 (24.8) 312 (75.2) 118 (28.1) 302 (71.9)
TB treatment historyi <.001 <.001
Current TB treatment 189 (19.1) 111 (50.7) 105 (57.4) 78 (42.6) 112 (59.6) 76 (40.4)
Prior TB treatment 129 (13.0) 20 (9.1) 19 (14.8) 109 (85.2) 21 (16.3) 108 (83.7)
No history of TB treatment 666 (67.1) 88 (40.2) 63 (9.7) 588 (90.3) 77 (11.6) 588 (88.4)
AFB smear statusj
≥1 AFB+ 152 (15.3) 133 (60.7) 131 (87.3) 19 (12.7) <.001 135 (88.8) 17 (11.2) <.001
2 AFB– 838 (84.5) 86 (39.3) 56 (6.8) 762 (93.2) 75 (9.0) 761 (91.0)
Final TB determination <.001 <.001
AFB+/TB culture positive 133 (13.4) 133 (60.7) 129 (98.5) 2 (1.5) 133 (100.0) 0 (0.0)
AFB–/TB culture positive 86 (8.7) 86 (39.3) 46 (54.8) 38 (45.2) 59 (69.4) 26 (30.6)
Clinical TB 57 (5.7) 0 (0.0) 2 (3.7) 52 (96.3) 4 (7.0) 53 (93.0)
Extrapulmonary TB 2 (0.2) 0 (0.0) 0 (0.0) 2 (100.0) 0 (0.0) 2 (100.0)
No TB 702 (70.8) 0 (0.0) 7 (1.0) 680 (99.0) 10 (1.4) 691 (98.6)
Indeterminate 12 (1.2) 0 (0.0) 3 (25.0) 9 (75.0) 4 (33.3) 8 (66.7)
Data are presented as No. (%) unless otherwise specified, with column percentages under the Overall and ≥1 Culture TB Positive results and row percentages under the Xpert results.
Abbreviations: AFB, acid-fast bacilli; AFB–, AFB smear negative; AFB+, AFB smear positive; ART, antiretroviral therapy; CXR, chest radiograph; HIV, human immunodeficiency virus; IQR,
interquartile range; TB, tuberculosis; Xpert, Xpert MTB/RIF assay.
a Xpert results on sputum sample #1. Invalid results (n = 20) and missing results due to site or laboratory errors (n = 2) were excluded.
b Per-participant Xpert results based on 2 sputum samples (positive = 1 or 2 Xpert-positive results; negative = 2 Xpert-negative or 1 negative plus 1 invalid/missing result). Invalid results (n = 2)
were excluded.
c χ2 test, except weight loss, night sweats, AFB status, and final TB determination (Fisher exact test), and age (Wilcoxon test).
d Participants may report >1 symptom.
e There were 21, 6, 6, 14, 8, and 13, respectively, participants whose presence of fever was unknown.
f There were 37, 4, 3, 33, 4, and 33, respectively, participants whose presence of weight loss was unknown.
g There were 25, 2, 3, 21, 3, and 22, respectively, participants whose presence of night sweats was unknown.
h Participants may have >1 abnormal CXR finding.
i There were 8, 0, 0, 8, 0, and 8, respectively, participants whose tuberculosis treatment history was unknown.
j There were 2, 2, 0, 2, 0, and 2, respectively, participants whose AFB status was unknown due to site/laboratory errors.
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Table 2. Xpert MTB/RIF Assay Sensitivity and Specificity Resultsa
Characteristic
Sensitivity Specificity
PPV NPVTB Culture Positive
AFB Smear Positive/
TB Culture Positive
AFB Smear Negative/
TB Culture Positive TB Culture Negative
All participants, first Xpert assay 81.4% (175/215) 98.5% (129/131) 54.8% (46/84) 98.7% (735/745) 94.6% (175/185) 94.8% (735/775)
[75.7%–86.0%] [94.6%–99.6%] [44.1%–65.0%] [97.5%–99.3%] [90.3%–97.0%] [93.0%–96.2%]
HIV status
HIV infected 73.6% (64/87)b 100.0% (39/39) 52.1% (25/48) 98.3% (339/345) 91.4% (64/70) 93.6% (339/362)
[63.4%–81.7%] [91.0%–100.0%] [38.3%–65.5%] [96.3%–99.2%] [82.5%–96.0%] [90.6%–95.7%]
HIV uninfected 86.7% (111/128)b 97.8% (90/92) 58.3% (21/36) 99.0% (396/400) 96.5% (111/115) 95.9% (396/413)
[79.8%–91.5%] [92.4%–99.4%] [42.2%–72.9%] [97.5%–99.6%] [1.4%–98.6%] [93.5%–97.4%]
Region
Low TB Prevalence (United states) 85.2% (75/88) 96.7% (59/61) 59.3% (16/27) 99.2% (526/530)c 94.9% (75/79) 97.6% (526/539)
[76.3%–91.2%] [88.8%–99.1%] [40.7%–75.5%] [98.1%–99.7%] [87.7%–98.0%] [95.9%–98.6%]
Higher TB prevalence (Brazil & South Africa) 78.7% (100/127) 100.0% (70/70) 52.6% (30/57) 97.2% (209/215)c 94.3% (100/106) 88.6% (209/236)
[70.8%–85.0%] [94.8%–100.0%] [39.9%–65.0%] [94.0%–98.7%] [88.2%–97.4%] [83.9%–92.0%]
Sputum collection
Induced 86.8% (59/68) 100.0% (50/50) 50.0% (9/18) 99.2% (254/256) 96.7% (59/61) 96.6% (254/263)
[76.7%–92.9%] [92.9%–100.0%] [29.0%–71.0%] [97.2%–99.8%] [88.8%–99.1%] [93.6%–98.2%]
Expectorated 77.4% (103/133) 97.2% (69/71) 54.8% (34/62) 98.2% (429/437) 92.8% (103/111) 93.5% (429/459)
[69.6%–83.7%] [90.3%–99.2%] [42.5%–66.6%] [96.4%–99.1%] [86.4%–96.3%] [90.8%–95.4%]
Sputum processing
Unprocessed 78.0% (32/41) 92.6% (25/27)d 50.0% (7/14) 99.1% (233/235) 94.1% (32/34) 96.3% (233/242)
[63.3%–88.0%] [76.6%–97.9%] [26.8%–73.2%] [97.0%–99.8%] [80.9%–98.4%] [93.1%–98.0%]
Concentrated 82.2% (143/174) 100.0% (104/104)d 55.7% (39/70) 98.4% (502/510) 94.7% (143/151) 94.2% (502/533)
[75.8%–87.2%] [96.4%–100.0%] [44.1%–66.8%] [96.9%–99.2%] [89.9%–97.3%] [91.9%–95.9%]
All participants, 2 Xpert assayse 88.1% (192/218) 100.0% (133/133) 69.4% (59/85) 97.9% (746/762) 92.3% (192/208) 96.6% (746/772)
[83.1%–91.7%] [97.2%–100.0%] [59.0%–78.2%] [96.6%–98.7%] [87.9%–95.2%] [95.1%–97.7%]
Data are presented as % (no./No.) [95% confidence interval].
Abbreviations: AFB, acid-fast bacilli; HIV, human immunodeficiency virus; NPV, negative predictive value; PPV, positive predictive value; TB, tuberculosis.
a Only positive and negative culture and Xpert results were included in these calculations. For the first Xpert assay, 3 failed cultures, 7 missing cultures due to site/laboratory error, 20 invalid Xpert results, and 2 missing Xpert results due to site/laboratory error
were excluded. For 2 Xperts, 3 failed cultures, 7 missing cultures due to site/laboratory error, and 2 invalid Xpert results were excluded.
b Fisher exact P = .020 for comparison of sensitivity by HIV status.
c Fisher exact P = .038 for comparison of specificity by region.
d Fisher exact P = .041 for comparison of sensitivity by sputum processing within AFB smear positive results.
e Two Xperts are per-participant Xpert results based on 2 sputum samples.
X
pert
in
U
S
vs
H
igher-P
revalence
Sites
•
C
ID
2016:62
(1
M
ay)
•
1085
specimen distinct from the AFB+ specimen that grew M. tubercu-
losis. In a third case, Xpert was invalid for a concentrated sputum
specimen distinct from the AFB+ specimen that grew M. tubercu-
losis. In the subset of 361 US participants (58%) with 3 AFB
smears available, 1 and 2 Xpert assays identified 82% (41/50)
and 88.5% (46/52), respectively, of culture-positive tuberculosis,
compared with 62.0% (31/50) and 61.5% (32/52) of culture-
positive tuberculosis identified with 3 AFB smears, respectively
(Table 3). One Xpert assay identified more than half of the
AFB–/culture-positive tuberculosis cases (11/19), which would be
missed entirely with initial AFB smears. In a secondary post hoc
analysis, a single negative Xpert assay predicted the absence of
AFB+/culture-positive tuberculosis with a negative predictive value
(NPV) of 99.7% (99.6% in the United States and 100% outside the
United States); the NPV was 100% for 2 negative Xpert assays.
Rifampin Resistance
Of the 200 culture-confirmed cases with rifampin susceptibility
results available, 3.5% (7/200) had rifampin resistance: 2 from
the United States, 4 from South Africa, and 1 from Brazil. The
first Xpert detected rifampin resistance in 5 of 7 (71.4%; 95%
CIs, 35.9–91.8%) culture-confirmed rifampin resistance cases.
Xpert did not detect either rifampin resistance or tuberculosis
in 2 participants with AFB–/culture-positive tuberculosis
whose M. tuberculosis from cultures were phenotypically resis-
tant to rifampin and had mutations in rpoB associated with ri-
fampin resistance (Supplementary Appendix Table 2). Testing
with 1 Xpert assay had a specificity for rifampin resistance of
99.5% (186/187; 95% CIs, 97.0–99.9%) and an NPV of 98.9%
(186/188; 95% CIs, 96.2–99.7%). In the 1 participant with
false-positive Xpert rifampin resistance testing, the first Xpert
indicated rifampin resistance, but the second did not. Sequenc-
ing of the cultured isolate did not show rpoB mutations.
Xpert Performance in HIV-Infected Participants
Xpert sensitivity was significantly lower in HIV-infected partic-
ipants (73.6%) than in HIV-uninfected participants (86.7%)
(P = .020; Table 2). However, when evaluated by AFB status,
sensitivity in AFB+ sputum (100% vs 97.8%) and AFB– sputum
(52.1% vs 58.3%) in HIV-infected and -uninfected persons, re-
spectively, did not differ (both P > .5). Overall specificity also
did not differ significantly between HIV-infected and -uninfected
participants (98.3% vs 99.0%; P = .53). Among 53 HIV-infected
participants with AFB– sputum, there was no evidence that Xpert
sensitivity was affected by CD4+ cell count (first Xpert assay,
P = .90; 2 Xpert assays, P = .58).
DISCUSSION
In the largest study to date evaluating the Xpert assay in settings
of low tuberculosis prevalence, the diagnostic performance of
Xpert in the United States was similar to higher-tuberculosis
prevalence sites in Brazil and South Africa, and was comparable
to other studies in higher-tuberculosis prevalence locations
[12]. These data support the use of Xpert as a diagnostic tool
in US patients undergoing initial evaluation for tuberculosis.
The current US algorithm for suspected tuberculosis recom-
mends respiratory isolation until 3 sputum smears collected at
least 8 hours apart are confirmed to be AFB– [13]. In our study,
1 Xpert assay identified 96% of AFB+/culture-positive tuberculosis
cases, and 2 Xpert assays identified all AFB+/culture-positive
Table 3. Sensitivity of Xpert MTB/RIF Assay Versus 2 or 3 Acid-Fast Bacilli Smears for Identification of US Culture-Confirmed Tuberculosis Cases
Smear AFB Positive 1 Xpert Positive Results P Value 2 Xpert Results, at Least 1 Positive P Value
2 AFB smears (n = 91a)
All 68.1%b (62/91)
[58.0%–76.8%]
85.2% (75/88)c
[76.3%–91.2%]
.001 91.1% (82/90)d
[83.4%–95.4%]
<.001
AFB positive 96.7% (59/61)d
[88.8%–99.1%]
100% (62/62)
[94.2%–100%]
AFB negative 59.3% (16/27)e
[40.7%–75.5%]
71.4% (20/28)d
[52.9%–84.7%]
3 AFB smears (n = 53)
All 60.4% (32/53)f
[46.9%–71.4%]
82.0% (41/50)c
[69.2%–90.2%]
.006 88.5% (46/52)d
[77.0%–94.6%]
<.001
AFB positive 96.8% (30/31)d
[83.8%–99.4%]
100% (32/32)
[89.3%–100%]
AFB negative 57.9% (11/19)e
[36.3%–76.9%]
70.0% (14/20)d
[48.1%–85.5%]
Data are presented as % (no./No.) [95% confidence interval]. P values are for comparison of AFB smear vs Xpert assay, using Fisher exact test.
Abbreviation: AFB, acid-fast bacilli.
a One missing Xpert due to site/laboratory error.
b AFB+ in 61 of 88 (69.3%) for 1 Xpert assay comparison and 62 of 90 (68.9%) for 2 Xpert assays comparison.
c Three invalid Xpert assays.
d One invalid Xpert assay.
e Two invalid Xpert assays.
f AFB+ in 31 of 50 (62.0%) for 1 Xpert assay comparison and 32 of 52 (61.5%) for 2 Xpert assays comparison.
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tuberculosis cases. One Xpert predicted the absence of culture-
positive tuberculosis with an NPV of 97.6%, and predicted the
absence of smear-positive tuberculosis with an NPV of 99.7%.
Importantly, 1 Xpert assay was significantly more sensitive than
3 AFB smears in the subset for whom 3 smears were available
(82.0% vs 61.5%; P < .001). A single Xpert assay identified more
than half of the AFB–/culture-positive tuberculosis cases, which
were missed entirely by AFB smears alone.
The benefit of a second Xpert to determine a need for contin-
ued respiratory isolation depends on the risk of a false-negative
initial Xpert result, the incremental yield of a second Xpert re-
sult, and the risk of undetected infectious tuberculosis. Cost-
benefit analysis may identify settings in which 1 Xpert alone
is adequate and others where a second Xpert is appropriate.
For those with HIV infection, a second Xpert may be quite im-
portant for prompt diagnosis regardless of smear status given
the morbidity and mortality associated with HIV/tuberculosis
coinfection. In addition, the impact of failure to identify even a
small number of patients with highly infectious smear-positive
tuberculosis must be considered in hospital settings where a
large number of more susceptible persons may be exposed.
In the United States, Xpert performance in the presence of
NTM is crucial, given the relatively high prevalence of NTM;
in this study, 12% of US participants had NTM growth. Xpert
performed well despite the presence of NTM; 1 Xpert assay
demonstrated specificity of 92% among participants with
NTM and excluded tuberculosis in 13 of 14 AFB+ participants
without culture-proven M. tuberculosis who commonly would
initiate tuberculosis treatment on the basis of AFB detection.
Previous data have indicated no cross-reactivity of Xpert with
multiple species of NTM [14], suggesting that the 5 false-posi-
tive Xpert results may indeed have had tuberculosis present that
was overgrown in culture by NTM. The contribution of excess
NTMDNAmaskingM. tuberculosisDNA polymerase chain re-
action amplification in the 2 participants with NTM and false-
negative Xpert results is not clear and merits further evaluation.
Rifampin resistance was uncommon in this study, limiting
our ability to evaluate Xpert to detect rifampin resistance. How-
ever, Xpert demonstrated a high NPV of 98.9% for exclusion of
rifampin resistance. Given the importance of prompt, accurate
identification of rifampin resistance, rapid molecular testing is
recommend to confirm rifampin resistance detected by Xpert,
and culture-based drug susceptibility testing is recommended
in all US tuberculosis cases [15].
It must be emphasized that 1 or more negative Xpert results,
like AFB smear [16], and even mycobacterial culture [17], does
not exclude the possibility of pulmonary tuberculosis. In addi-
tion to molecular testing, US guidelines recommend collection
of at least 3 respiratory samples for AFB smear and mycobacte-
rial culture during initial evaluation of suspected respiratory tu-
berculosis, and drug susceptibility testing when M. tuberculosis
is recovered [15, 18].
In summary, these results demonstrate that the Xpert assay is a
valuable addition to the tuberculosis armamentarium in the
United States and, potentially, other lower-prevalence settings
where the assay can facilitate initial diagnosis of tuberculosis
and can be used in conjunction with other clinical information
as part of the algorithm for initial respiratory isolation decisions.
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